Table 1.

Patient characteristics

Patient demographics	IG-IMRT (n = 35)		IMRT (n = 67)		p-value (Fisher)
	Number	Percent	Number	Percent
Pre-treatment PSA (ng/ml)*					p = 0.169
< 10	15	42.9	41	62.1
10–20	9	25.7	10	15.2
> 20	11	31.4	15	22.7
Total Gleason score*					p = 0.082
< 7	3	8.8	5	7.5
7	10	29.4	8	11.9
> 7	21	61.8	54	80.6
T’stage*					p = 0.026
T1c-T2a	10	28.6	34	52.3
T2b	9	25.7	6	9.2
> T2b	16	45.7	25	38.5
Radiation dose delivered					p = 1.000
86.4 Gy	34	97.1	66	98.5
84.6 Gy	0	0.0	1	1.5
82.. 8 Gy	1	2.9	0	0.0
Age (y)					p = 0.071
< 70	12	34.3	37	55.2
> 70	23	65.7	30	44.8
Neoadjuvant ADT					p = 1.000
Yes	30	42.9	57	42.5
No	5	7.1	10	7.5
Positioning					p < 0.001
Prone	1	2.9	65	97.0
Supine	34	97.1	2	3.0
Number of risk factors**					p = 0.215
1	10	28.6	31	46.3
2	18	51.4	27	40.3
3	7	20.0	9	13.4

Abbreviations: PSA Prostate Specific Antigen, ADT Androgen Deprivation

Therapy

*One, one and two of the patients lacked information on pre-treatment PSA, Gleason score and T stage, respectively

^**Counting the number of risk factors as defined as PSA > 10, T Stage >T2c and total Gleason score > 7